The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review

Hodge, William; Lachaine, J.; Steffensen, I; Murray, Christine; Barnes, David; Foerster, Vicki; Ducruet, Thiérry; Morrison, Andra

doi:10.1136/bjo.2007.123737

Cited by 47 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…146 The pooled summary estimate significantly favored latanoprost (weighted mean difference (WMD) = 1.10, 95% CI 0.57 to 1.63) over brimonidine. A third meta-analysis 158 did not find a significant reduction in mean IOP when latanoprost was compared with brimonidine (WMD = −1.04; P = 0.30). This pooled result did not change when only two higherquality studies 70,76 were analyzed; one study part funded by Pharmacia 70 favored latanoprost (adjusted mean diurnal IOP reduction = 5.7 mmHg) over brimonidine (3.1 mmHg) and the other study supported by Allergan 76 did not find a significant difference between treatments; mean %IOPR was 27.8% vs 27.0% for latanoprost and brimonidine respectively.…”

Section: Vs Brimonidinementioning

confidence: 93%

“…132 Compared with latanoprost, ocular adverse effects were similar to dorzolamide. 158 Ocular discomfort 188 and stinging 133 was greater with FCDT. Ocular hyperemia was found to be similar for brimonidine and latanoprost use in one review 158 but converse in a meta-analysis.…”

Section: Tolerance Medication Persistency and Patient-focused Perspementioning

confidence: 96%

“…158 Ocular discomfort 188 and stinging 133 was greater with FCDT. Ocular hyperemia was found to be similar for brimonidine and latanoprost use in one review 158 but converse in a meta-analysis. 89 Serious ocular adverse events were similar between brimonidine and latanoprost; ocular inflammation (0.7% vs 1.3%) and CME (0.3% vs 1.3%).…”

Section: Tolerance Medication Persistency and Patient-focused Perspementioning

confidence: 96%

“…Hodge et al 158 also compared latanoprost with dorzolamide through a meta-analysis of 3 studies 75,159,160 (n = 328). Mean IOP was lower in the latanoprost compared with the dorzolamide group (WMD = −2.64 mmHg; P , 0.00001).…”

Section: Vs Dorzolamidementioning

confidence: 99%

See 3 more Smart Citations

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPlowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1-to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

show abstract

Section: Vs Brimonidinementioning

confidence: 93%

Section: Tolerance Medication Persistency and Patient-focused Perspementioning

confidence: 96%

Section: Tolerance Medication Persistency and Patient-focused Perspementioning

confidence: 96%

Section: Vs Dorzolamidementioning

confidence: 99%

See 2 more Smart Citations

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

show abstract

“…4,5 Of all current therapies utilized in the treatment of POAG associated with raised IOP, prostaglandin analogues (PGAs) demonstrate consistent superiority over beta-adrenergic blockers (eg, betaxolol), alpha-adrenergic agonists (eg, brimonidine) or a topical carbonic anhydrase inhibitor (dorzolamide) therapies as far as IOP-lowering efficacy is concerned. [6][7][8] More invasive treatment strategies, such as surgery, may be effective, but also can result in severe adverse events and population-heavy costs. 9,10 Prostaglandin analogues lower IOP by increasing the uveoscleral outflow of aqueous humor.…”

Section: Dovepressmentioning

confidence: 99%

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Eyawo

Nachega

Lefèbvre

et al. 2009

OPTH

View full text Add to dashboard Cite

Background: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed. Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins. Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I 2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I 2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I 2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P  0.001, I 2 = 97%, 95% CI, 95 to 98, P  0.001). Five trials assessing latanoprost and bimatoprost revealed an elevated risk of conjunctival hyperemia with bimatoprost (RR 1.59, 95% CI, 1.02 to 2.48, P = 0.04, I 2 = 76%, 95% CI, 16 to 88, P = 0.002). Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.

show abstract

Quantitative determination of a novel enantiomeric tropane analog, (−)‐satropane, in biological fluids using liquid chromatography/tandem mass spectrometry

Fang

Cui

et al. 2009

Biomedical Chromatography

View full text Add to dashboard Cite

A sensitive, accurate and precise liquid chromatography-tandem mass spectrometry method was developed for the determination of (-)-satropane (3alpha-paramethyl-benzenesulfonyloxy-6beta-acetoxy-tropane) in rabbit aqueous humor. Since (-)-satropane may be absorbed from the aqueous humour with resultant systemic side effects, the LC-MS/MS method was also evaluated for its applicability in analyzing plasma samples containing this compound. (-)-Satropane and phentolamine (the internal standard, represented as IS) were detected by multiple reaction monitoring using the transitions m/z 354-182 and 282-212, respectively. The calibration curve was linear over the ranges 2-500 and 5-1000 ng/mL, and the values of the lower limit of quantification were 2 and 5 ng/mL for the microdialysis dialysate and rat plasma samples, respectively. The intra-day and inter-day precision and accuracy were better than 8.6 and 6.00%, respectively, in both matrices investigated. The absolute recovery of the plasma samples was more than 76.30%. The average matrix effects of (-)-satropane were 91.72 and 83.05% in the microdialysis dialysate and plasma samples, respectively. The validated method was successfully applied to analyze (-)-satropane in microdialysis dialysate and rat plasma samples, and this assay has been used to quantify (-)-satropane in the pharmacokinetic and toxicokinetic studies in our laboratory.

show abstract

The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review

Cited by 47 publications

References 29 publications

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Quantitative determination of a novel enantiomeric tropane analog, (−)‐satropane, in biological fluids using liquid chromatography/tandem mass spectrometry

Contact Info

Product

Resources

About